Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M John Chapman

Showing results (11-20 of 235) with videos related to

Pageof 24
Sort By:
Current Opinion in Lipidology|June 29, 2010
Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activitiesAnatol Kontush, M John Chapman
Arteriosclerosis, Thrombosis, and Vascular Biology|April 22, 2006
A new dimension in the vasculoprotective function of HDL: progenitor-mediated endothelium repairPhilippe Lesnik, M John Chapman
Atherosclerosis. Supplements|April 27, 2002
Optimizing the pharmacology of statins: characteristics of rosuvastatinM John Chapman, Fergus McTaggart
Arteriosclerosis, Thrombosis, and Vascular Biology|July 25, 2008
HDL: close to our memories?Anatol Kontush, M John Chapman
Current Atherosclerosis Reports|April 29, 2010
Lipidomics as a tool for the study of lipoprotein metabolismAnatol Kontush, M John Chapman
Current Opinion in Lipidology|June 13, 2022
Sphingosine-1-phosphate: metabolism, transport, atheroprotection and effect of statin treatmentPatrice Therond, M John Chapman
Nature Clinical Practice. Cardiovascular Medicine|March 1, 2006
Antiatherogenic small, dense HDL--guardian angel of the arterial wall?Anatol Kontush, M John Chapman
Current Diabetes Reports|March 28, 2008
Why is HDL functionally deficient in type 2 diabetes?Anatol Kontush, M John Chapman
Arteriosclerosis, Thrombosis, and Vascular Biology|November 25, 2005
Mechanisms of statin-induced myopathy: a role for the ubiquitin-proteasome pathway?M John Chapman, Alain Carrie
Pharmacological Reviews|September 14, 2006
Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosisAnatol Kontush, M John Chapman
Pageof 24

Showing results (11-20 of 235) with videos related to

Sort By:
Pageof 24
Current Opinion in Lipidology|June 29, 2010
Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activitiesAnatol Kontush, M John Chapman
Arteriosclerosis, Thrombosis, and Vascular Biology|April 22, 2006
A new dimension in the vasculoprotective function of HDL: progenitor-mediated endothelium repairPhilippe Lesnik, M John Chapman
Atherosclerosis. Supplements|April 27, 2002
Optimizing the pharmacology of statins: characteristics of rosuvastatinM John Chapman, Fergus McTaggart
Arteriosclerosis, Thrombosis, and Vascular Biology|July 25, 2008
HDL: close to our memories?Anatol Kontush, M John Chapman
Current Atherosclerosis Reports|April 29, 2010
Lipidomics as a tool for the study of lipoprotein metabolismAnatol Kontush, M John Chapman
Current Opinion in Lipidology|June 13, 2022
Sphingosine-1-phosphate: metabolism, transport, atheroprotection and effect of statin treatmentPatrice Therond, M John Chapman
Nature Clinical Practice. Cardiovascular Medicine|March 1, 2006
Antiatherogenic small, dense HDL--guardian angel of the arterial wall?Anatol Kontush, M John Chapman
Current Diabetes Reports|March 28, 2008
Why is HDL functionally deficient in type 2 diabetes?Anatol Kontush, M John Chapman
Arteriosclerosis, Thrombosis, and Vascular Biology|November 25, 2005
Mechanisms of statin-induced myopathy: a role for the ubiquitin-proteasome pathway?M John Chapman, Alain Carrie
Pharmacological Reviews|September 14, 2006
Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosisAnatol Kontush, M John Chapman
Pageof 24